Therapix Biosciences Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals development. Led by a seasoned team of executives and scientists, the company is focused on expanding its portfolio of technologies and assets. The company’s drug development programs are based on tetrahydrocannabinol (THC) and non-psychoactive cannabidiol (CBD). The programs include THX-110 for treating Tourette syndrome and obstructive sleep apnea, THX-160 for pain relief, and THX-210 for treating autism spectrum disorder and epilepsy.